Molecular Formula | C16H12F3N3S |
Molar Mass | 335.35 |
Density | 1.40 |
Melting Point | 127-128.2°C |
Boling Point | 512.6±50.0 °C(Predicted) |
Solubility | DMSO: 32mg/mL |
Appearance | solid |
Color | white |
pKa | 3.42±0.10(Predicted) |
Storage Condition | 2-8°C |
MDL | MFCD06411432 |
Use | SL327 |
In vitro study | SL327 is a structural homolog of the specific MKK1/2 inhibitor U0126, which is water-soluble. When inhibiting MEK1 and MEK2, The IC50 is 0.18 μm and 0.22 μm, respectively. SL327 has no inhibitory effect on many other kinases, including PKA, PKC, or CamKII. |
In vivo study | SL327 (50 mg/kg) can penetrate the blood-brain barrier and inhibit conditioned fear by inhibiting MAPK/ERK phosphorylation. SL327(30 mg/kg) significantly impaired spatial learning and memory in mice. SL327(50 mg/kg) inhibits Cocaine-induced properties. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.982 ml | 14.91 ml | 29.82 ml |
5 mM | 0.596 ml | 2.982 ml | 5.964 ml |
10 mM | 0.298 ml | 1.491 ml | 2.982 ml |
5 mM | 0.06 ml | 0.298 ml | 0.596 ml |
biological activity | SL-327 is a selective MEK1/2 inhibitor with an IC50 of 0.18 μm/0.22 μm, there was no inhibitory activity against Erk1, MKK3, MKK4, c-JUN, PKC, PKA, and CamKII, able to pass the blood-brain barrier. SL-327 is a selective MEK1/2 inhibitor with an IC50 of 0.18 μm/0.22 μm, against Erk1, MKK3, MKK4, c-JUN, PKC, PKA, and CamKII has no inhibitory activity and can pass the blood-brain barrier. |
Target | Value |
MEK1 () | 0.18 μM |
MEK2 | 0.22 μM |
AP-1 | 2.03 μM |